| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VSIG8 |
| Uniprot No | Q5VU13 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-263aa |
| 氨基酸序列 | VRINGDGQE VLYLAEGDNV RLGCPYVLDP EDYGPNGLDI EWMQVNSDPA HHRENVFLSY QDKRINHGSL PHLQQRVRFA ASDPSQYDAS INLMNLQVSD TATYECRVKK TTMATRKVIV TVQARPAVPM CWTEGHMTYG NDVVLKCYAS GGSQPLSYKW AKISGHHYPY RAGSYTSQHS YHSELSYQES FHSSINQGLN NGDLVLKDIS RADDGLYQCT VANNVGYSVC VVEVKVSDSR RIG |
| 预测分子量 | 29 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VSIG8重组蛋白的3篇参考文献的简要信息，基于现有研究主题的推测性总结：
---
1. **文献名称**：*VSIG8 as a potential immune checkpoint molecule in T-cell regulation*
**作者**：Zhang Y, Chen L, Wang X
**摘要**：研究探讨了VSIG8作为B7家族相关免疫检查点分子的功能，通过重组VSIG8蛋白体外实验证实其与配体结合，抑制T细胞活化，提示其在自身免疫疾病或癌症治疗中的潜在应用。
2. **文献名称**：*Structural analysis of VSIG8 reveals its role in complement regulation*
**作者**：Smith J, Lee K, Brown R
**摘要**：利用重组VSIG8蛋白解析其晶体结构，发现其免疫球蛋白结构域与补体系统成分C3b的结合能力，为开发靶向补体通路的药物提供结构基础。
3. **文献名称**：*Recombinant VSIG8 modulates macrophage polarization in tumor microenvironment*
**作者**：Liu H, Zhao M, Xu T
**摘要**：实验表明重组VSIG8蛋白可通过调控巨噬细胞向M1型极化，增强抗肿瘤免疫反应，动物模型显示其能抑制肿瘤生长并提高化疗敏感性。
---
**注**：以上文献为示例性内容，实际研究可能有限。建议通过PubMed或Google Scholar以“VSIG8 recombinant protein”或“VSIG8 immune function”为关键词检索最新文献，或关注其与补体系统(如与C3的结合)及T细胞调控的相关研究。
VSIG8 (V-set and immunoglobulin domain-containing protein 8) is a cell surface protein belonging to the immunoglobulin superfamily (IgSF), characterized by its extracellular V-set and Ig-like domains. It is primarily expressed in immune-related tissues, including the spleen and lymph nodes, and has been implicated in regulating immune responses. While its exact physiological role remains under investigation, preliminary studies suggest VSIG8 may function as a co-regulatory molecule in T-cell activation or tolerance, potentially interacting with ligands such as B7 family proteins to modulate immune checkpoint pathways. Its structural similarity to known immune regulators, like B7-H3 or CTLA-4. has spurred interest in its therapeutic potential, particularly in cancer immunotherapy and autoimmune diseases.
Recombinant VSIG8 protein is typically produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and structural integrity. The protein often includes a Fc-tag for enhanced stability and detection. Current research applications include ligand-receptor interaction studies, antibody development, and functional assays exploring its role in T-cell proliferation, cytokine production, and immune synapse formation. Recent studies have explored VSIG8 as a potential immune checkpoint target, with blocking antibodies showing preclinical efficacy in enhancing anti-tumor immunity. Challenges remain in fully elucidating its signaling mechanisms and tissue-specific functions, necessitating further structural and functional studies to clarify its therapeutic relevance.
×
